Linoleic acid
- Generic Name
- Linoleic acid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H32O2
- CAS Number
- 60-33-3
- Unique Ingredient Identifier
- 9KJL21T0QJ
- Associated Conditions
- Acne, Dermatitis, Dry Skin
- Associated Therapies
- Parenteral Nutrition
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
- Conditions
- HIV-1-infectionPregnancyPostpartum
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 45
- Registration Number
- NCT06336434
- Locations
- 🇺🇸
Site 4601, University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States
🇺🇸Site 5048, University of Southern California LA, Los Angeles, California, United States
🇺🇸Site 5013, Jacobi Medical Center Bronx, Bronx, New York, United States
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT05112939
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 55
- Registration Number
- NCT04824131
- Locations
- 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇿🇦Ward 21 CRS, Johannesburg, Gauteng, South Africa
🇿🇼Spilhaus CRS, Harare, Zimbabwe
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 9
- Registration Number
- NCT04692077
- Locations
- 🇺🇸
St. Jude Children's Research Hosp. ATN CRS, Memphis, Tennessee, United States
🇺🇸John H. Stroger Jr. Hosp. of Cook County ATN CRS, Chicago, Illinois, United States
🇺🇸The Fenway Institute ATN CRS, Boston, Massachusetts, United States
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
- Conditions
- HIV Infections
- Interventions
- Drug: Oral CABDrug: Oral TDF/FTCDrug: Placebo for oral CABDrug: Placebo for CAB LADrug: Placebo for oral TDF/FTCDrug: CAB LA
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-09-30
- Target Recruit Count
- 3224
- Registration Number
- NCT03164564
- Locations
- 🇿🇼
St Mary's CRS, Chitungwiza, Zimbabwe
🇧🇼Gaborone CRS, Gaborone, South-East District, Botswana
🇺🇬MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
- Conditions
- HIV Infections
- Interventions
- Drug: Cabotegravir Oral TabletDrug: TDF/FTC tabletsDrug: Placebo for cabotegravir oral tabletDrug: Placebo for CAB LADrug: Placebo for TDF/FTC tabletsDrug: CAB LA
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-11-25
- Target Recruit Count
- 4570
- Registration Number
- NCT02720094
- Locations
- 🇵🇪
San Miguel CRS, Lima, Peru
🇺🇸Penn Prevention CRS, Philadelphia, Pennsylvania, United States
🇺🇸Fenway Health (FH) CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.